Infections, Respiratory Tract Clinical Trial
Official title:
A Phase I, Randomized, Double-Blinded, Placebo- and Moxifloxacin-Controlled, 4-Period Crossover Study to Evaluate the Effect of GSK2140944 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers
This is Phase I, 4-period, randomized, active-and placebo-controlled, double-blind crossover,
single-dose study to evaluate the effects of a therapeutic (1000 milligram [mg]) and
supratherapeutic (1800 mg) dose of GSK2140944 with a positive control (moxifloxacin 400 mg)
and placebo on the corrected QT interval (QTc) as assessed by continuous 12-lead Holter
electrocardiograms (ECGs) in approximately 55 healthy volunteers.
All subjects will receive single doses of GSK2140944 1000 mg, GSK2140944 1800 mg,
moxifloxacin 400 mg, and placebo in a randomized sequence. A double-dummy approach will be
used to maintain blinding. Thus, on each dosing day, moxifloxacin or moxifloxacin placebo and
GSK2140944 or placebo will be administered.
Subjects will be screened within 30 days prior to entry to the clinic. Subjects will report
to the clinical unit on Day -2 of Period 1 and on Day -1 in subsequent periods. Subjects will
remain confined until check out procedures have been completed on Day 3 (5 days confinement
in Period 1 and 4 days in the following 3 periods). There will be a washout of at least 7
days between doses. The follow-up visit will occur 7-10 days after the final dose. Total
duration of the study (from screening to the follow-up visit) will be approximately 60 days.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02202187 -
A Single Oral Escalating Dose Study of GSK2140944 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT01706315 -
This Study Will Investigate the Safety, Tolerability and Pharmacokinetic Profile of Repeat Oral Doses of GSK2140944 in Healthy Adult Subjects
|
Phase 1 | |
| Completed |
NCT02000765 -
A Study to Investigate the Recovery, Excretion and Pharmacokinetics of [14C]-GSK2140944 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects
|
Phase 1 | |
| Completed |
NCT04600752 -
Study to Evaluate the Safety and Clinical Efficacy of Augmentin® Extra Strength-600 in Children With Acute Otitis Media in India
|
Phase 4 | |
| Terminated |
NCT01292213 -
A Study to Identify and Characterise Bacteria Causing Chronic Cough Among Children in United Kingdom
|
N/A | |
| Completed |
NCT01772238 -
Bioequivalence Study of an Amoxicillin-Clavulanic
|
Phase 1 | |
| Completed |
NCT01615796 -
Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Repeat IV Doses
|
Phase 1 | |
| Completed |
NCT02169583 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects
|
Phase 1 | |
| Completed |
NCT01353768 -
Zanamivir Aqueous Solution Compassionate Use Program Retrospective Chart Review Study
|
N/A | |
| Completed |
NCT01767532 -
Bioequivalence Study of Cephalexin Suspension 125
|
Phase 1 | |
| Completed |
NCT01767571 -
Bioequivalence Study of Cephalexin Suspension 250
|
Phase 1 | |
| Completed |
NCT01510938 -
Probiotics in Respiratory Tract Infections in Children
|
Phase 2 | |
| Completed |
NCT00354965 -
Pharmacokinetic Profiles Of Amoxicillin 2000 mg And Clavulanate 125 mg In Adolescent Patients
|
Phase 1 | |
| Completed |
NCT02688361 -
A Bioequivalence Study of an Acetylcysteine 2% Oral Solution Versus a Reference Fluimucil 2% Oral Solution
|
Phase 1 | |
| Withdrawn |
NCT02678234 -
An Efficacy and Safety Study of Theraflu Day Powder as Oral Solution for Cold and Flu
|
Phase 3 | |
| Withdrawn |
NCT02730364 -
An Efficacy and Safety Study of Theraflu Night Powder as Oral Solution for Cold and Flu
|
Phase 3 | |
| Completed |
NCT01767584 -
Bioequivalence Study of Cephalexin Tablets 1g
|
Phase 1 |